Cell populations which co-express CD49c and CD90

US9969977B2 · kind B2 · utility

Assignee

• GARNET BIOTHERAPEUTICS, INC. · US

Inventors

• Tony Ho · Malvern, US
• Gene Kopen · Lansdowne, US
• William Righter · Swarthmore, US
• J. Rutkowski · Lansdowne, US
• Joseph Wagner · West Chester, US
• W. Herring · Valley Forge, US
• Vanessa Ragaglia · Newtown Square, US

Key dates

• Filing date: Sep 20, 2002
• Grant date: May 15, 2018
• Expiry date: Jan 19, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2506/11
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous population of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.